Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 80 28 DAY versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 80 28 DAY versus PIRMELLA 7 7 7.
NORINYL 1+80 28-DAY vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive